Bayer HealthCare **Pharmaceuticals**

Fax

Re



RECEIVED CENTRAL FAX CENTER

JAN 17 2006

Commissioner for Patents To U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 (571) 273-8300 Pages Fax January 17, 2006 Date Susan M. Pellegrino From (203) 812-6450 Tel. (203) 812-6459

U.S. Patent Application Serial No.: 10/521,538

Bayer Pharmaceuticals Corporation

400 Morgan Lane West Haven, CT 06516

Phone: Fax:

(203) 812-6450 (203) 812-6459

E-mail:

susan.pellegrino.b@bayer.com

For U.S. Patent Application Serial No. 10/521,538

- 1) Reply to Office Action mailed on November 17, 2005
- Certificate of Transmission under 37 CFR 1.8
- 3) Fax Cover Sheet

If you have any problems with the attached facsimile call (203) 812-6450.

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT THE PRIVILEGED OR CONFIDENTIAL NATURE OF THIS MESSAGE IS NOT WAIVED BY INADVERTENT DISCLOSURE. ANY DISSEMINATION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

PTO/SB/97 (05-03)
Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on January 17, 2006

Date

Susan M. Lelliquis Signature

Susan M. Pellegrino, Reg. No. 48,972

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

For U.S. Patent Application Serial No. 10/521,538

- 1) Reply to Office Action mailed on November 17, 2005
- 2) Certificate of Transmission under 37 CFR 1.8
- 3) Fax Cover Sheet

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No. LeA 35 926

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

In re Patent Application of Achim Feurer, et al.

JAN 17 2006

Serial No.: 10/521,538

Group Art Unit: 1624

Filed: August 1, 2005

Examiner: Deepak R. Rao

For: Novel 2,5-Disubstituted Pyrimidine Derivatives

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being facsimile transmitted to the U.S. Patent and Trudemark Office at (571) 273-8300.

Date: January 17, 2006

Susan M. Pellegrino

REPLY AND AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action mailed November 17, 2005 (Paper No. 11142005), Applicants respectfully request reconsideration and reexamination of the present application in view of the following amendments and remarks.

AMENDMENTS

IN THE CLAIMS:

Kindly amend the claims as follows:

Please cancel claims 7 and 9.

Please amend claims 1-4, 8, and 10-12, as shown in the attached sheets (pages 4-9).